GAD-7: What the Generalized Anxiety Disorder 7-Item Scale Measures
Updated: Oct 8
Author: Ukrainian Psychological Hub · Published: September 30, 2026 · Editorial Policy
The GAD-7, short for the Generalized Anxiety Disorder 7-item scale, is a brief self-report questionnaire that measures how often a person has been bothered by seven anxiety-related symptoms during the previous two weeks. It was developed to help identify probable generalized anxiety disorder (GAD) and to quantify anxiety symptom severity, and it is now used widely in primary care, mental health care, research, and measurement-based care.
The most important fact about the GAD-7 is also the easiest to lose in online scoring pages: it measures recent self-reported symptom frequency. It does not by itself establish a psychiatric diagnosis, explain why the symptoms are occurring, determine whether they have lasted long enough to meet criteria for GAD, identify the correct anxiety disorder, rule out a medical or substance-related cause, or decide what treatment a particular person needs.
Each of the seven items is rated from 0 to 3 according to frequency, producing a total score from 0 to 21. A higher total means that the symptoms covered by the questionnaire were reported more frequently across the two-week window. The number is therefore a compact measure of recent symptom burden, not a percentage of “how anxious” someone is and not a probability that the person has GAD.
This article explains the construct the GAD-7 measures, what its seven items capture, how the total score is built, how screening differs from diagnosis, what current diagnostic-accuracy evidence shows, how the scale can be used to monitor change, and where its limits become clinically important. For the broader clinical framework, see Anxiety Disorders: Symptoms, Types, Diagnosis, and Treatment.
What Does the GAD-7 Measure?
In one sentence, the GAD-7 measures the frequency of seven recent anxiety symptoms, with particular emphasis on generalized worry, difficulty controlling worry, tension or arousal, restlessness, irritability, difficulty relaxing, and fearful anticipation. The seven responses are summed to create a single anxiety-symptom severity score.
That wording matters. The scale does not directly measure every symptom that can occur in anxiety, every feature required for a diagnosis of generalized anxiety disorder, or every anxiety disorder. It samples a focused set of symptoms and converts their reported frequency over two weeks into one standardized score.
The original validation study by Spitzer and colleagues described the GAD-7 as a brief self-report scale intended to identify probable cases of GAD and assess severity. The study was conducted in 15 U.S. primary care clinics; 2,740 adults completed the questionnaire and 965 received a follow-up telephone interview with a mental health professional. This origin explains both the name of the scale and its strong association with primary-care screening.
Where the GAD-7 Came From
The GAD-7 was published in 2006. Its developers began with a larger pool of possible anxiety items, including symptoms derived from the then-current DSM-IV description of GAD and items informed by existing anxiety measures. They asked how often each problem had been present during the previous two weeks and selected a seven-item set that performed well as a brief clinical measure.
The original paper reported good reliability and several forms of validity. Increasing scores were associated with greater functional impairment and disability, and a threshold was identified that balanced sensitivity and specificity for probable GAD in that primary-care study. Those results established the GAD-7 as a useful screening and severity instrument; they did not transform a questionnaire score into a stand-alone diagnosis.
Since 2006, the scale has been studied in general-population samples, psychiatric settings, medical populations, adolescents, perinatal populations, multiple languages, and different countries. That broader evidence supports its usefulness as a compact anxiety measure, while also showing why accuracy estimates and score interpretation depend on population, language, setting, and purpose.
The Seven Symptom Domains in the GAD-7
The seven scored items are not seven separate diagnoses. Together they sample a cluster of experiences that commonly travel with generalized anxiety and broader anxious distress. The official wording is freely available for use, but understanding what the items are trying to capture is more useful than memorizing the form.
Nervousness and Feeling on Edge
One item captures a general state of nervousness, anxiety, or being on edge. This is a broad arousal and distress signal. It can occur in GAD, panic-related conditions, social anxiety, phobic fear, depression with anxious distress, trauma-related conditions, medication or substance effects, medical conditions, and ordinary periods of stress. Its presence therefore contributes to an anxiety-severity score without identifying a cause.
Difficulty Stopping or Controlling Worry
A second item focuses on perceived difficulty stopping or controlling worry. This is especially relevant to GAD because difficulty controlling worry is central to the clinical syndrome. Yet the questionnaire asks about the recent frequency of this experience; it does not establish the longer duration, context, impairment, or exclusions needed for diagnosis.
Excessive Worry Across Different Things
Another item asks about worrying too much about different things. It samples the breadth of worry, one reason the scale is well aligned with generalized anxiety rather than a fear restricted to a single object or situation. The item still cannot determine whether the worries are disproportionate, whether they are tied to real-life stressors, or whether another disorder better explains their content.
Trouble Relaxing
Trouble relaxing captures the sustained activation that often accompanies anxiety. It can reflect cognitive tension, physical tension, or both. Because sleep loss, pain, stimulant use, medical illness, depression, acute stress, and other factors can also make relaxation difficult, this item is informative about symptom burden rather than etiology.
Restlessness
Restlessness adds a behavioral and bodily dimension. A person may feel unable to sit comfortably, driven to move, keyed up, or physically unsettled. Restlessness is relevant to GAD, but it is also nonspecific and can occur in many psychiatric, medical, medication-related, and situational contexts.
Irritability
Irritability broadens the scale beyond fear and worry. Chronic anxious arousal can reduce frustration tolerance and make a person feel easily annoyed. Irritability also appears in mood disorders, sleep deprivation, stress reactions, substance-related states, neurodevelopmental conditions, pain, and other contexts, so it should never be read as uniquely diagnostic of anxiety.
Fearful Anticipation
The final item captures a sense that something bad may happen. This reflects anticipatory threat: anxiety oriented toward a possible future danger rather than a confirmed present threat. It is clinically meaningful, but its content remains deliberately broad. A clinician still needs to ask what the feared outcome is and what pattern of symptoms surrounds it.
Why the GAD-7 Produces One Total Score
The conventional GAD-7 treats the seven responses as indicators of a common anxiety-severity dimension and sums them with equal weight. Each response receives 0, 1, 2, or 3 points, so the total can range from 0 to 21. There are no reverse-scored items and no diagnostic algorithm hidden behind the arithmetic.
Psychometric work supports the idea that the items often behave as a largely unidimensional scale. A large German general-population validation study involving 5,030 participants supported a one-dimensional structure and reported strong internal consistency. A later item-response-theory analysis in 3,404 primary-care patients also supported unidimensionality, while showing that individual items did not contribute identical amounts of information across the anxiety continuum.
That finding does not mean readers should invent a weighted GAD-7 score. Clinical and research interpretation is based on the validated conventional scoring system. It does mean that a total score is a summary statistic: two people can reach the same total through different combinations of symptoms, and those item-level differences may matter in a clinical conversation.
The Two-Week Timeframe Is Part of What the Scale Measures
The GAD-7 asks about the previous two weeks. This gives the measure a clear reference period and makes repeated administrations easier to compare. It also creates a crucial diagnostic boundary: a two-week symptom snapshot cannot establish the chronicity required for generalized anxiety disorder.
The National Institute of Mental Health describes GAD diagnosis as requiring difficulty controlling worry on most days for at least six months, together with associated symptoms and clinically meaningful impact. A person can therefore have a high recent GAD-7 score during an acute crisis without meeting the full criteria for GAD, while another person with a longer-standing anxiety disorder can have a lower score during an unusually good two-week period.
The reference period should also be preserved when monitoring change. Asking someone to answer based on “how you usually feel,” the last month, or the last few days changes the construct being measured and weakens comparability with the validated scale.
What the GAD-7 Score Represents
The GAD-7 total represents the summed frequency of the seven covered symptoms during the specified two-week window. Higher scores generally indicate greater recent anxiety symptom burden. The score can be useful for screening, describing baseline severity, comparing groups in research, or tracking symptom change over time.
The total does not represent a probability of having GAD. A score of 12, for example, is not a statement that someone has a 12-out-of-21 degree of generalized anxiety disorder, a 57% chance of GAD, or a fixed clinical severity independent of setting. Diagnostic probability depends on far more than the score, including the population being screened, the prevalence of the condition, symptom history, impairment, differential diagnosis, and the threshold chosen for a particular use.
The score also does not reveal which symptoms are driving the total. Reviewing the individual responses can therefore be clinically useful. A total dominated by uncontrollable worry may prompt different follow-up questions from the same total dominated by restlessness, irritability, and fearful anticipation.
The Functional-Difficulty Question Is Separate From the Seven-Item Score
Standard GAD-7 forms commonly include a follow-up question asking how difficult the reported problems have made work, home responsibilities, or relationships. That functional-impact question is clinically useful, but it is not one of the seven scored items and does not contribute to the 0–21 total.
This distinction prevents a common misunderstanding. The GAD-7 total primarily quantifies symptom frequency. Functional impairment is related to symptom severity—the original validation study found higher scores associated with greater impairment—but impairment should still be assessed directly. Two people with similar symptom totals can have very different levels of disability because of context, coping resources, avoidance, responsibilities, support, and the specific situations affected.
GAD-7 Screening Is Not the Same as GAD Diagnosis
Screening asks whether a pattern is sufficiently suggestive to justify closer evaluation. Diagnosis asks whether the person meets the full clinical criteria for a specific disorder after alternatives and exclusions have been considered. The GAD-7 is useful in the first task and can contribute information to the second, but it cannot perform the second task alone.
This matters because current GAD diagnosis depends on a broader pattern than the seven scored questions. Duration is one difference: GAD requires a persistent pattern over months, while the GAD-7 covers two weeks. Symptom coverage is another. Current diagnostic criteria include associated features such as fatigue, concentration difficulty, muscle tension, and sleep disturbance that are not directly scored by the GAD-7. Clinical assessment also considers distress or impairment, substance or medication effects, medical causes, and whether another mental disorder better explains the anxiety.
A high GAD-7 score can therefore occur without GAD, and GAD cannot be confirmed from the score alone. Conversely, a lower score does not automatically rule GAD out. Screening tools make information more efficient; they do not replace the history, differential diagnosis, and clinical judgment that give the information meaning. For the direct relationship between a GAD-7 screen and a clinical GAD diagnosis, see GAD-7 and Generalized Anxiety Disorder: Screening vs Diagnosis.
How Accurate Is the GAD-7?
Accuracy depends on what condition is being detected, which cutoff is used, who is being screened, the setting, the language version, and the diagnostic interview used as the comparison standard. One sensitivity-and-specificity pair should not be treated as a permanent property of the questionnaire.
The Original Primary-Care Study
In the 2006 development study, a selected cutoff produced sensitivity of 89% and specificity of 82% for GAD in the study population. These figures are historically important, but they came from one development and validation context. They should not be copied into every population as though the same performance were guaranteed.
The 2016 Diagnostic Meta-Analysis
A 2016 systematic review and diagnostic meta-analysis pooled 12 samples with 5,223 participants. It found acceptable performance for identifying GAD across several nearby cutoffs, while also emphasizing the need for additional validation. This synthesis helped establish that the scale's usefulness extended beyond the original study, but it also showed that threshold performance varies.
The 2025 Cochrane Review
A much larger Cochrane diagnostic-accuracy review published in 2025 included 48 studies with 19,228 participants from 27 countries and 24 languages. For detecting GAD at a threshold of 10 or the closest available value, the review estimated summary sensitivity of 0.64 and specificity of 0.91. For detecting any anxiety disorder, sensitivity was lower while specificity remained high. The review also found substantial heterogeneity between studies.
The practical meaning is straightforward. The GAD-7 can be a useful signal, but some people with GAD will screen below a chosen threshold and some people above it will not have GAD. The Cochrane authors explicitly concluded that the GAD-7 and GAD-2 cannot by themselves diagnose or rule out an anxiety disorder.
Why Prevalence Changes the Meaning of a Positive Result
Sensitivity and specificity are properties estimated from a study sample at a chosen threshold. The probability that a person who screens positive actually has GAD also depends on how common GAD is in the population being tested. A positive result in a high-risk clinical population and the same result in a low-prevalence general population do not carry identical diagnostic meaning.
This is one reason professional screening recommendations pair questionnaires with follow-up assessment. The U.S. Preventive Services Task Force notes that people who screen positive for anxiety should receive further evaluation for diagnosis and, when appropriate, evidence-based care.
What a Positive GAD-7 Screen Means
A positive screen means that the person's pattern of responses crossed a threshold selected to flag clinically relevant anxiety symptoms or possible GAD. It raises the reason to ask more questions. It does not specify the final diagnosis.
Follow-up usually clarifies the timeline of worry and anxiety, the situations or thoughts that trigger it, the degree of control over worry, associated physical and cognitive symptoms, avoidance and safety behaviors, functional impairment, co-occurring depression or other psychiatric symptoms, medication and substance use, and relevant medical conditions. The exact assessment depends on the clinical context.
The screen can ultimately lead to several different conclusions: GAD, another anxiety disorder, a different psychiatric condition, anxiety associated with a medical or substance-related state, a subthreshold presentation, or a temporary stress response. The questionnaire cannot choose among those possibilities by itself.
What a Negative GAD-7 Screen Means
A score below a chosen threshold reduces concern for the target condition in the context where that threshold has evidence, but it does not prove that no anxiety disorder is present. Diagnostic tests with imperfect sensitivity produce false negatives, and a two-week questionnaire can miss fluctuating symptoms or a disorder whose defining features are poorly represented by the seven items.
Someone can also have clinically important panic attacks, social fear, phobic avoidance, separation fear, trauma-related symptoms, obsessive-compulsive symptoms, health anxiety, or another form of distress without generating a high GAD-7 total. If the history suggests a specific problem, assessment should follow the problem rather than stop because one broad questionnaire was low.
Does the GAD-7 Measure General Anxiety or Generalized Anxiety Disorder?
Both descriptions are used, and the difference reflects how the scale evolved. The GAD-7 was designed around generalized anxiety disorder and remains particularly relevant to GAD. At the same time, studies have found that it behaves as a broader anxiety symptom measure in many clinical settings.
In a heterogeneous psychiatric sample, researchers found support for the GAD-7 as a measure of general anxiety symptoms beyond a narrowly defined GAD population. The 2025 Cochrane review also evaluated its ability to detect “any anxiety disorder,” although diagnostic accuracy was weaker for that broader target than for GAD.
The safest interpretation is therefore dimensional. The GAD-7 tells us about a person's recent burden on seven anxiety-related symptoms. That burden may be relevant to GAD and may also rise in other conditions. The name of the scale should not be mistaken for a guarantee that the underlying disorder is GAD.
What the GAD-7 Does Not Measure Well
No seven-item instrument can represent the full clinical territory of anxiety. The GAD-7 is intentionally brief, and brevity creates omissions that are essential to understand.
It Does Not Measure the Full GAD Diagnostic Criteria
The scale does not directly score the six-month duration requirement, the complete set of associated GAD symptoms, the exclusion of substances or medical conditions, or the full differential diagnosis. It is therefore a symptom measure aligned with GAD, not a checklist that mechanically reproduces the diagnostic criteria.
It Is Not a Panic-Attack Measure
The GAD-7 does not systematically ask about the abrupt surge of fear and the characteristic physical and cognitive symptoms that define a panic attack. A person with panic disorder may score high because they are anxious between attacks, but panic disorder requires its own history and diagnostic questions.
It Is Not a Social-Anxiety or Phobia Measure
The questionnaire does not identify fear of scrutiny, humiliation, specific animals, heights, flying, needles, enclosed spaces, or other disorder-specific fear targets. A person with severe avoidance can therefore have important impairment that is poorly summarized by a generalized anxiety score. For the broader distinctions among diagnoses, see Types of Anxiety Disorders: GAD, Panic, Phobias, Social Anxiety, and More.
It Does Not Diagnose OCD, PTSD, or Other Neighboring Conditions
Obsessive-compulsive disorder and trauma-related disorders can involve intense anxiety, but current classification systems place them outside the core anxiety-disorders category. The GAD-7 does not assess obsessions, compulsions, trauma exposure, intrusive trauma memories, or the other features needed to characterize those disorders. Elevated anxiety symptoms may coexist with them without changing their diagnostic identity.
It Does Not Determine Medical Cause
A questionnaire cannot establish whether anxiety-like symptoms are primarily psychiatric, medical, medication-related, substance-related, or produced by several factors at once. New or concerning physical symptoms, changes after medication or substance exposure, and relevant medical history require appropriate clinical evaluation rather than an assumption that a high GAD-7 score explains the cause.
It Does Not Assess Suicide Risk
There is no self-harm or suicide item in the GAD-7. A low, moderate, or high GAD-7 score therefore says nothing definitive about suicidal thoughts or immediate safety. When safety concerns are present, they require direct assessment rather than inference from an anxiety score.
GAD-7 Versus GAD-2
The GAD-2 consists of the first two GAD-7 items and focuses on general nervousness or anxiety plus difficulty controlling worry. It is even shorter and is often used as an initial screening step when time is limited.
The 2025 Cochrane review found no statistically significant difference between the overall diagnostic accuracy of GAD-7 and GAD-2 in its comparative analyses. That does not make the instruments interchangeable for every purpose. The seven-item version captures a broader symptom profile and provides a wider severity range, while the two-item version minimizes response burden.
A common workflow is to use the very brief tool for initial case finding and the longer scale when more information or longitudinal severity measurement is useful. The appropriate choice depends on the service, population, and purpose.
Can the GAD-7 Track Change Over Time?
Yes. Repeated GAD-7 scores are often used to monitor anxiety symptoms during care, because the scale is short, standardized, and anchored to the previous two weeks. This is one of its most useful roles when the same person completes the same validated version at comparable intervals.
Studies support responsiveness to change. A 2020 study of sensitivity to change found that GAD-7 scores moved in the expected direction across treatment follow-up and estimated a minimal clinically important difference of about four points in that particular sample. Other work has produced somewhat different estimates, which is a reminder that a single universal “meaningful change” number should not be applied mechanically across populations and baseline severities.
A falling score can support the conclusion that recent symptoms are improving; a rising score can signal worsening or a need to reassess. Neither direction proves why the change occurred. Treatment, life events, sleep, physical illness, medication changes, substance use, measurement variability, and ordinary symptom fluctuation can all affect repeated scores.
For monitoring to be meaningful, clinicians should look at the trajectory, the individual items, functional change, the person's own account, treatment adherence and adverse effects when relevant, and the broader clinical picture. The questionnaire is a measurement aid, not an automated treatment verdict.
Reliability, Validity, and Psychometric Evidence
Three different ideas are often collapsed into the phrase “the GAD-7 is validated.” They should be kept separate. Reliability concerns how consistently the items measure their underlying construct. Construct validity concerns whether the score behaves as expected in relation to anxiety and other variables. Diagnostic accuracy concerns how well a chosen score threshold distinguishes people who do and do not meet a diagnostic reference standard.
The 2008 general-population study by Löwe and colleagues reported strong internal consistency and supported a one-factor structure. The 2017 item-response-theory study provided additional support for a dominant anxiety dimension while showing that the seven items differ in how much information they provide at different severity levels. These results support the scale as a coherent symptom measure.
High internal consistency does not prove that the scale diagnoses GAD accurately. Seven items can correlate strongly with one another and still produce false positives and false negatives when compared with a diagnostic interview. That is why psychometric reliability, screening performance, and diagnostic validity must remain distinct concepts.
Cross-Cultural and Language Use
The GAD-7 is used internationally, but a translated questionnaire is not automatically psychometrically equivalent to the original. Translation quality, cultural interpretation of anxiety language, health-system context, and response patterns can affect measurement.
A 2026 systematic review of cross-cultural validity evaluated nine eligible studies covering 11,894 participants and 20 cultural groups. Most studies supported a unitary structure, and the studies that directly examined cultural bias found little effect on the overall score. The authors nevertheless judged the cross-cultural evidence base to be limited and called for more high-quality research.
The appropriate conclusion is neither that the GAD-7 works identically everywhere nor that international use is unsupported. The available evidence is encouraging, but users should prefer validated language versions and population-specific evidence when making consequential clinical or research decisions.
Use in Adolescents and Other Populations
The original development study was an adult primary-care study. Later research has examined the GAD-7 in younger people and specialized populations, but evidence from one group should not be imported into another without checking how the instrument performed there.
For adolescents, psychometric studies generally support the scale as an anxiety symptom measure. A clinical study of adolescents with confirmed GAD found that GAD-7 scores tracked clinical symptom severity, while other large adolescent studies have supported reliability and a one-factor structure. These findings do not justify assuming that every adult cutoff has identical diagnostic meaning in children or adolescents. Developmental context and age-appropriate assessment remain important.
The same principle applies in pregnancy and postpartum care, chronic medical illness, psychiatric specialty settings, and culturally diverse populations. A scale can remain useful while its optimal threshold, false-positive rate, false-negative rate, or interpretation changes with the setting. The large Cochrane review found meaningful heterogeneity across study populations and settings, which is exactly what clinicians should expect from a brief screening instrument used in many different contexts.
Why GAD-7 Scores Can Be Elevated in Depression
Anxiety and depression frequently co-occur, and several GAD-7 symptoms—such as restlessness, irritability, difficulty relaxing, or generalized distress—can rise when a person is depressed. The original validation study found that anxiety and depressive symptoms were related but distinguishable dimensions.
An elevated GAD-7 in a person with depression therefore should not be dismissed as “just depression,” and it should not automatically be labeled GAD. The result signals clinically relevant anxiety symptoms that deserve clarification. Assessment can then determine whether the person has comorbid GAD, another anxiety disorder, anxious distress within a mood presentation, stress-related symptoms, or another explanation.
Why the Same GAD-7 Score Can Mean Different Things in Different People
A total score compresses seven responses and two weeks of experience into one number. Compression is useful for communication and tracking, but it removes detail. Two people with the same total can differ in symptom profile, chronicity, impairment, triggers, avoidance, medical context, co-occurring conditions, and risk.
One person may have long-standing generalized worry that has impaired work and sleep for years. Another may have an acute two-week rise in anxiety after a major life event. A third may have panic disorder and spend the interval worrying about another attack. A fourth may have medication-induced restlessness and apprehension. Their totals can look similar even though their clinical formulations and next assessment steps differ substantially.
This is why the score works best as structured information inside a clinical process, not as a label placed on a person. If you want the broader distinction between symptoms and disorder-level impairment, see What Is an Anxiety Disorder? Definition, Signs, and Clinical Thresholds and Anxiety: When Normal Worry and Fear Become a Disorder.
How Clinicians Can Use the GAD-7 Well
Good use begins by preserving the validated task: the person rates the seven symptoms for the previous two weeks. The clinician can then review the individual responses and total, ask about functional impact, and place the result in a timeline.
The next step is not “diagnose from the score.” It is to clarify the clinical pattern. That includes the content and controllability of worry; whether fear is generalized or organized around panic, social evaluation, a specific object, separation, illness, trauma, or another theme; how long the pattern has persisted; what the person avoids; and how daily functioning is affected.
The assessment also considers psychiatric comorbidity, medications and substances, relevant medical conditions, sleep, acute stressors, and safety when indicated. When GAD is suspected, the clinician compares the full history with current diagnostic requirements rather than treating the GAD-7 as a substitute for them.
If the scale is repeated, the trend can be combined with the person's subjective improvement, functioning, treatment goals, side effects, and other outcome measures. This keeps measurement-based care patient-centered rather than score-centered.
Can You Take the GAD-7 Online?
Yes. The GAD-7 is widely available in paper and digital formats. Pfizer announced in 2010 that the PHQ and GAD-7 assessment tools could be accessed and used without copyright restriction and at no charge. That has helped make the scale easy to integrate into clinics, research platforms, and digital health systems.
The fact that a questionnaire is freely available does not make every online implementation equally good. A responsible version should preserve the validated wording and timeframe, calculate the score correctly, explain that the result is screening or severity information rather than a diagnosis, and make its data-handling practices clear if responses are stored or transmitted.
Taking the GAD-7 privately can help a person organize what they have been experiencing and can provide a useful starting point for a conversation with a clinician. It should not be used to rule out a disorder, explain medically concerning symptoms, or choose prescription treatment without appropriate assessment.
GAD-7 and the Broader Anxiety-Disorders Map
The GAD-7 is one node in a larger assessment system. Anxiety itself is a symptom dimension, while anxiety disorders are distinct clinical syndromes with different defining fears, worry patterns, avoidance, duration rules, developmental considerations, and differential diagnoses. See Anxiety Symptoms: Emotional, Cognitive, Physical, and Behavioral Signs for the wider symptom landscape.
A broad anxiety questionnaire is useful precisely because it gives a common language across settings. Its limit is the same feature: common language can blur diagnostic boundaries if the score is asked to do more than it was designed to do. The right interpretation keeps both levels in view—the dimensional signal of anxiety symptoms and the categorical question of which, if any, disorder is present.
Frequently Asked Questions About the GAD-7
What does GAD-7 stand for?
GAD-7 stands for Generalized Anxiety Disorder 7-item scale. The name reflects its origin as a brief measure developed to identify probable GAD and assess symptom severity.
How many questions are on the GAD-7?
There are seven scored symptom items. Standard forms also commonly include a separate functional-difficulty question, but that follow-up item is not included in the 0–21 total.
What period of time does the GAD-7 cover?
The seven items ask about the previous two weeks. That short reference period makes the scale useful for recent severity measurement and repeated monitoring, but it cannot establish the longer duration required for a diagnosis of GAD.
What is the maximum GAD-7 score?
The seven items are each scored from 0 to 3, so the maximum total is 21 and the minimum is 0. The total is a sum of symptom-frequency responses. Detailed interpretation of score bands and thresholds requires context because screening performance varies across populations and purposes.
Can the GAD-7 diagnose generalized anxiety disorder?
No. It can identify a pattern that makes GAD more or less likely and can quantify recent symptoms, but diagnosis requires the full history, duration, impairment, exclusions, differential diagnosis, and clinical assessment.
Can someone have GAD with a low GAD-7 score?
Yes. No screening tool has perfect sensitivity, symptoms can fluctuate, and the two-week window may not capture the person's usual level. A low score should be interpreted alongside the history and current clinical question.
Can someone have a high GAD-7 score without GAD?
Yes. Other anxiety disorders, depression with prominent anxiety, acute stress, trauma-related conditions, medical or substance-related states, and other presentations can produce high anxiety symptom scores. A high total signals symptom burden and the need for interpretation; it does not specify the diagnosis.
Does the GAD-7 measure panic attacks?
Not specifically. Some people with panic disorder score high because of ongoing anxiety and apprehension, but the GAD-7 does not systematically measure the sudden surge and characteristic symptom pattern of panic attacks.
Is GAD-7 the same thing as an anxiety test?
It is an anxiety screening and severity questionnaire, but the phrase “anxiety test” is broader and can refer to many instruments. Different measures target different disorders, age groups, symptom domains, or purposes.
Can the GAD-7 be used to monitor treatment?
Yes. Repeated scores can help track recent anxiety symptoms, and research supports sensitivity to change. The trend should be interpreted with functioning, the person's experience, treatment context, and other clinical information rather than as a stand-alone measure of success or failure.
Is the GAD-7 free to use?
Pfizer has made the GAD-7 available without copyright restriction and at no charge for reproduction, translation, display, and distribution. Users should still preserve the instrument accurately and distinguish the original questionnaire from any modified or locally adapted version.
The Bottom Line
The GAD-7 measures how frequently seven anxiety-related symptoms have bothered a person over the previous two weeks. Its strength is efficiency: seven short items can turn a diffuse clinical experience into a standardized severity signal that is useful for screening, communication, research, and repeated measurement.
Its limits are equally clear. The score does not establish GAD, does not identify the cause of symptoms, does not cover every anxiety disorder, does not replace assessment of impairment and duration, and does not rule medical or psychiatric alternatives in or out. The best use of the GAD-7 is therefore as a measurement tool inside a larger assessment process.
That distinction is the core answer to the search query. The GAD-7 measures recent anxiety symptom frequency and severity. Diagnosis belongs to the clinical pattern, not to the questionnaire score.
Related Articles
References
Aktürk, Z., Hapfelmeier, A., Fomenko, A., et al. (2025). Generalized Anxiety Disorder 7-item (GAD-7) and 2-item (GAD-2) scales for detecting anxiety disorders in adults. Cochrane Database of Systematic Reviews, 2025(3), CD015455. https://www.cochrane.org/evidence/CD015455_how-accurate-are-gad-7-and-gad-2-questionnaires-detecting-anxiety-disorders.
Beard, C., & Björgvinsson, T. (2014). Beyond generalized anxiety disorder: Psychometric properties of the GAD-7 in a heterogeneous psychiatric sample. Journal of Anxiety Disorders, 28(6), 547–552. https://pubmed.ncbi.nlm.nih.gov/24983795/.
Jordan, P., Shedden-Mora, M. C., & Löwe, B. (2017). Psychometric analysis of the Generalized Anxiety Disorder scale (GAD-7) in primary care using modern item response theory. PLOS ONE, 12(8), e0182162. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0182162.
Löwe, B., Decker, O., Müller, S., et al. (2008). Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Medical Care, 46(3), 266–274. https://pubmed.ncbi.nlm.nih.gov/18388841/.
Mantzari, A., Botella-Juan, L., Yadav, P., et al. (2026). Cross-cultural validity of the generalized anxiety disorder 7-item scale (GAD-7): A systematic review and standardized assessment. Epidemiology and Psychiatric Sciences, 35, e24. https://pubmed.ncbi.nlm.nih.gov/41968509/.
Mossman, S. A., Luft, M. J., Schroeder, H. K., et al. (2017). The Generalized Anxiety Disorder 7-item scale in adolescents with generalized anxiety disorder: Signal detection and validation. Annals of Clinical Psychiatry, 29(4), 227–234A. https://pubmed.ncbi.nlm.nih.gov/29069107/.
National Institute of Mental Health. (2024). Generalized Anxiety Disorder: What You Need to Know. https://www.nimh.nih.gov/health/publications/generalized-anxiety-disorder-gad.
Pfizer. (2010). Pfizer to offer free public access to mental health assessment tools to improve diagnosis and patient care. https://www.pfizer.com/news/press-release/press-release-detail/pfizer_to_offer_free_public_access_to_mental_health_assessment_tools_to_improve_diagnosis_and_patient_care.
Plummer, F., Manea, L., Trepel, D., & McMillan, D. (2016). Screening for anxiety disorders with the GAD-7 and GAD-2: A systematic review and diagnostic meta-analysis. General Hospital Psychiatry, 39, 24–31. https://pubmed.ncbi.nlm.nih.gov/26719105/.
Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006). A brief measure for assessing generalized anxiety disorder: The GAD-7. Archives of Internal Medicine, 166(10), 1092–1097. https://pubmed.ncbi.nlm.nih.gov/16717171/.
Toussaint, A., Hüsing, P., Gumz, A., et al. (2020). Sensitivity to change and minimal clinically important difference of the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7). Journal of Affective Disorders, 265, 395–401. https://pubmed.ncbi.nlm.nih.gov/32090765/.
U.S. Preventive Services Task Force. (2023). Anxiety disorders in adults: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/anxiety-adults-screening.